CRSP250103C39000
- 2.50
- +0.40+19.05%
CRISPR Therapeutics Newsroom
CRISPR Therapeutics AG's (NASDAQ:CRSP) Recent 4.5% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?
Cathie Wood's ARK Investment Bought 58K Shares of Crispr Therapeutics Today
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for Investors
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
JMP Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $86
CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing
1 Big New Green Flag for CRISPR Therapeutics' Stock
Express News | JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target
Clear Street Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $45
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
Crispr Therapeutics Call Volume Above Normal and Directionally Bullish
Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $105
3 Things You Need to Know If You Buy CRISPR Therapeutics Today
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?
Chardan Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $94
Evercore Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
Crispr Therapeutics AG (CRSP) Gets a Hold From Evercore ISI
Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Silence Therapeutics (SLN)
Express News | Chardan Capital Maintains Buy on CRISPR Therapeutics, Maintains $94 Price Target